Oramed extends Scilex note maturity to Dec 2025; receives 3.25M Scilex shares as consideration

ORAMED PHARMACEUTICALS INC.

Remaining principal on Tranche A Note is $7.675M; maturity extended from March 21, 2025 to December 31, 2025.
SCLX JV transferred 3,250,000 shares of Scilex common stock to Oramed as consideration for the extension.
Note covenants amended: cash sweep definition updated, and Scilex may not increase officer/director compensation while note outstanding.
Oramed may waive certain prepayments and instead direct prepayment to Tranche B Note holders.
Extension was a condition for payment deferrals under separate Tranche B Note amendments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.